Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Vascular Diseases 2Heart Diseases 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Second Primary 1Metabolic Diseases 1Heart Failure 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Cancer Metastatic 1Cardiovascular Diseases 1Cardiotoxicity 1Cancer Therapy-related Cardiovascular Toxicity 1Breast Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × Antineoplastic Agents × Clear all
NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Immunicom Inc

Phase 1/2 Unknown
170 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡